Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Fodosine forodesine hydrochloride: Additional Phase I/II data

Additional data from an open-label, dose-escalation Phase I/II trial in 36 patients with refractory CTCL showed

Read the full 167 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE